Aina Martínez-Planas, Fernando Baquero-Artigao, Ana Méndez-Echevarría, Teresa Del Rosal, Paula Rodríguez-Molino, Carlos Toro-Rueda, Matilde Bustillo-Alonso, Miguel Lafuente, Anna Canet, Ángela Manzanares, Alfredo Tagarro, Francisco José Sanz-Santaeufemia, Sara Guillén-Martín, María José Cilleruelo, Lola Falcón-Neyra, Begoña Santiago, Elena Rincón, Miguel Lillo, Antoni Soriano-Arandes, Luigi Sedda, Clàudia Fortuny, Manuel Monsonís, Julián González-Martín, Marc Tebruegge, Antoni Noguera-Julian
{"title":"A 28-Year Multicenter Cohort Study of Nontuberculous Mycobacterial Lymphadenitis in Children, Spain","authors":"Aina Martínez-Planas, Fernando Baquero-Artigao, Ana Méndez-Echevarría, Teresa Del Rosal, Paula Rodríguez-Molino, Carlos Toro-Rueda, Matilde Bustillo-Alonso, Miguel Lafuente, Anna Canet, Ángela Manzanares, Alfredo Tagarro, Francisco José Sanz-Santaeufemia, Sara Guillén-Martín, María José Cilleruelo, Lola Falcón-Neyra, Begoña Santiago, Elena Rincón, Miguel Lillo, Antoni Soriano-Arandes, Luigi Sedda, Clàudia Fortuny, Manuel Monsonís, Julián González-Martín, Marc Tebruegge, Antoni Noguera-Julian","doi":"10.3201/eid3103.241254","DOIUrl":null,"url":null,"abstract":"<p>We describe the epidemiology, diagnosis, and management of nontuberculous mycobacterial lymphadenitis cases detailed in a 28-year (1996–2023) multicenter cohort from Spain. The case numbers remained stable during the initial prospective phase (2013–2020), but a sharp decline was observed during 2021–2022. Disease onset occurred during spring or June in 45.9% of cases. <em>Mycobacterium avium</em> complex (43.1%) and <em>M</em>. <em>lentiflavum</em> (39.9%) were the most common species detected. <em>M</em>. <em>lentiflavum</em> affected mostly younger children from central Spain. The most common treatment strategy was complete surgical resection with (n = 80) or without (n = 88) antimicrobial drug treatment, followed by antimicrobial drugs alone (n = 76). Facial palsy developed in 10.4% of surgical cases. Adverse events because of antimicrobial drugs were uncommon. New fistula formation during follow-up occurred more in children managed with observation alone than in those treated with antimicrobial drugs alone (relative risk 2.7 [95% CI 1.3–5.3]; p = 0.014).</p>","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":"52 1","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3103.241254","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We describe the epidemiology, diagnosis, and management of nontuberculous mycobacterial lymphadenitis cases detailed in a 28-year (1996–2023) multicenter cohort from Spain. The case numbers remained stable during the initial prospective phase (2013–2020), but a sharp decline was observed during 2021–2022. Disease onset occurred during spring or June in 45.9% of cases. Mycobacterium avium complex (43.1%) and M. lentiflavum (39.9%) were the most common species detected. M. lentiflavum affected mostly younger children from central Spain. The most common treatment strategy was complete surgical resection with (n = 80) or without (n = 88) antimicrobial drug treatment, followed by antimicrobial drugs alone (n = 76). Facial palsy developed in 10.4% of surgical cases. Adverse events because of antimicrobial drugs were uncommon. New fistula formation during follow-up occurred more in children managed with observation alone than in those treated with antimicrobial drugs alone (relative risk 2.7 [95% CI 1.3–5.3]; p = 0.014).
期刊介绍:
Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination.
Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.